

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Single Technology Appraisal (STA)

Sorafenib for advanced hepatocellular carcinoma

Response to consultee and commentator comments on the provisional matrix of consultees and commentators (pre-referral)

Version of matrix of consultees and commentators reviewed: Provisional matrix of consultees and commentators sent for consultation				
Summary of comments, action taken, and justification of action:				
	<i>Proposal:</i>	<i>Proposal made by:</i>	<i>Action taken:</i> Removed/Added/Not included/Noted	<i>Justification:</i>

National Institute for Health and Clinical Excellence

Response to comments on the provisional matrix of consultees and commentators (pre-referral) for the appraisal of sorafenib for advanced hepatocellular carcinoma

Issue date: August 2008

1.	We note that whilst the Cancer Networks Pharmacist group is amongst the consultees the cancer networks themselves do not seem to be included. This appears to us to be an omission	Oxfordshire PCT	Removed	<i>These organisations do not fit the inclusion criteria in regards to national organisations therefore cancer networks have not been added</i>
----	--	-----------------	---------	---

National Institute for Health and Clinical Excellence

Response to comments on the provisional matrix of consultees and commentators (pre-referral) for the appraisal of sorafenib for advanced hepatocellular carcinoma

Issue date: August 2008